Back to Results
First PageMeta Content
Immunology / Drugs / Targeted therapy / Ovarian cancer / Monoclonal antibodies / Bevacizumab / Breast cancer treatment / Medicine / Pharmacology / Immune system


GAMAMABS PHARMA One line pitch: Gamamabs develops innovative antibodies which activate effector cells in oncology. Gamamabs lead antibody is in pre-IMPD stage and targets AMHRII in ovarian cancer Market Analysis:
Add to Reading List

Document Date: 2015-03-26 10:59:50

Open Document

File Size: 799,08 KB

Share Result on Facebook

Company

Omnes Capital / Degove Stéphane / /

Continent

Europe / /

Country

France / United States / /

Currency

EUR / USD / /

/

IndustryTerm

antibody technology / glyco-engineering antibody technology / /

MedicalCondition

chemo-resistant ovarian cancer / tumor / ovarian cancer / endometrial cancer / burn / cancer / gynecologic cancers / /

MedicalTreatment

chemo / chemotherapy / chemotherapies / /

Person

Irdinov / Prost Jean-François / Pierre Potier / /

Position

CEO / VP R&D / /

Product

avastin / /

Technology

glyco-engineering antibody technology / Humabfc antibody technology / antibodies / chemotherapy / /

URL

WWW.gamamabs.com / /

SocialTag